Dr. Arora submitted his resignation effective close of business hours on September 15, 2026, to pursue career opportunities outside the organization. He will complete his handover period and be relieved from duties on the same date.
The resignation was formally communicated through a letter dated September 15, 2026, addressed to the Managing Director of AstraZeneca Pharma India Limited. In his resignation letter, Dr. Arora expressed gratitude to senior management and colleagues for their support during his tenure.
The company has confirmed that this position qualifies as Senior Management Personnel under SEBI Listing Regulations and has provided the required details as per SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, which includes:
- Name & Designation: Dr. Sandeep Arora, Director - Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit
- Reason for change: Resignation to pursue his career outside the Company
- Date of cessation: Effective close of business hours on September 15, 2026
- Term of appointment: Not applicable
- Brief Profile: Not applicable
The company is currently in the process of looking for a suitable replacement for this position. The disclosure was signed by Tanya Sanish, Company Secretary & Compliance Officer, on September 15, 2026, at 11:47:23 IST.